ATIVA’s rapid low-cost COVID-19 test may provide earlier detection and a safer community

 

The greatest challenge we face is the spread of infection before symptoms appear. We all want to protect our loved ones, so how do we know if we are infected? Physical symptoms (fever, cough) appear too late to stop the spread, antibodies appear even later. The nasal swab PCR test suffers from sampling errors, slow time to results, and is quite expensive. Early detection of infected people is the key to protecting our most vulnerable people in assisted-living centers, cancer wards, our valued frontline workers (EMTs, nurses) and our essential workers in critical infrastructure or food processing jobs.

Ativa’s COVID-19 test works very differently than the antibody and PCR tests in use today

 

Using just a drop of blood, Ativa’s test may detect the body’s earliest immune response to infection, well before symptoms appear or antibodies emerge. There are very subtle but detectable changes in the white blood cells morphology and ratios within hours of infection. This is the innate immune response, and no other test is measuring this today. Ativa’s test is completed within 5-minutes and at the point-of-care.

 

Ativa’s low-cost COVID-19 screening test will help triage individuals, enabling nasal-swab PCR testing to acheive a much higher detection rate, protecting our community.

How does it work?

Using advanced A.I. algorithms, Ativa detects the early innate immune cell changes in blood (see image below). These include NK-cells, phagocytes, activated lymphocytes, T-cells, white cell ratios, nuclear-cytoplasm ratios and shifts in absolute cell counts. In viral infections, blood cell changes occur days before physical symptoms appear. Emerging evidence on blood changes during COVID-19 disease progression supports Ativa’s approach for detection, monitoring, staging and prognosis on disease severity. Ativa can even track the immune system recovery from mild to severe COVID cases and the body’s response to vaccines that trigger the immune cells.

When will it be available?

Ativa is rapidly developing and validating this new test, with clinical studies underway. After FDA-approval, this test will be made available as quickly and widely as possible.

When the SARS-CoV-2 virus first enters the throat and lungs, the innate immune system is activated within hours to label and destroy the virus. Later, the adaptive immune system begins to produce antibodies.
When the SARS-CoV-2 virus first enters the throat and lungs, the innate immune system is activated within hours to label and destroy the virus. Later, the adaptive immune system begins to produce antibodies.

Use this form to request more information about Ativa’s COVID-19 Testing solution.